If the past three years have shown us anything, it’s that healthcare organizations are capable of rising to the occasion in even the most trying of circumstances.
But if pandemic-era pressures have eased a bit, their aftereffects are still being felt as we move into 2023. Hospitals and health…
From: www.healthcareitnews.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
